Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
Medpace is a global full-service CRO providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease.
Established in 1992 in Cincinnati, Ohio, Medpace is historically a US based company. Since its inception, it has remained a physician led, therapeutically focused, CRO. Over the course of 20 years Europe has become an increasingly important market region. A full-time office in Lyon opened in 2012, while Medpace has been conducting business operations in France since 2005. Currently they have thirteen offices in Europe and have established themselves as an international CRO with a strong European presence.
Contact
Medpace France
235 cours Lafayette
69006 Lyon
France
Tel: +33 4 37 53 09 91
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
